"The rest of the portfolio performed incredibly well," Ricks said Tuesday. "If you stripped away incretins and GLP-1s from the pharma sector, the balance of Lilly would probably be the fastest ...

"If you stripped away incretins and GLP-1s from the pharma sector, the balance of Lilly would probably be the fastest-growing big company in the sector." ...

Lilly said on Tuesday it had expected the market for incretins to grow faster, based on the performance in previous quarters. As supply normalizes, Lilly's Chief Financial Officer Lucas Montarce ...

MOE Key Laboratory of Bio-Intelligent Manufacturing, State Key Laboratory of Fine Chemicals, Frontiers Science Centre for Smart Materials Oriented Chemical Engineering, School of Bioengineering, ...